Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients
Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs,
With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood
A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary
Veradermics has succeeded in its first major test as a newly-minted public company.
The biotech’s form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair loss, producing …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844